In a multicenter phase 2 study (Alliance A091401, NCT02500797), nivolumab (i.e., an anti-PD-1) alone or in combination with ipilimumab (i.e., an anti-CTLA-4) was tested in sarcoma patients who had received at least one previous line of systemic therapy; in the combination therapy arm, the objective response rate (ORR) was 16%, and responses occurred in UPS, MFS, and leiomyosarcoma subtypes with manageable safety profiles of combined treatment, similar to other therapeutic interventions (76, 77). The gene discussed is PDCD1; the disease is sarcoma.